Texas Oncology-Paris

Paris, Texas 76022

1 studies enrolling now · 14 studies all time

What they study most

Advanced Breast Cancer, Anorexia, Breast Adenocarcinoma, Breast Cancer, Cachexia, Cancer, Colorectal Cancer, Estrogen Receptor Negative, Estrogen Receptor Positive Tumor, Fatigue, HER2/Neu Negative, Loss of Appetite

Studies at this site

• TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers — Recruiting now
• Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer — Completed
• Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) — Running, not enrolling
• Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer — Running, not enrolling
• Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) — Completed
• Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer — Completed
• Palbociclib in Real World Practice — Completed
• Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) — Status unconfirmed
• Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia — Completed
• Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer — Completed
• A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer — Withdrawn before enrolling
• A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer — Completed
• An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry) — Completed
• A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors — Completed